Posted by Michael Wonder on 14 Jan 2021
Innovation Pharmaceuticals’ brilacidin for the treatment of COVID-19 receives FDA fast track designation
14 January 2021 - Innovation Pharmaceuticals is pleased to announce that the U.S. FDA has designated as a fast track development program the investigation of brilacidin as a potential treatment for COVID-19.
Brilacidin is a first in class host defense protein mimetic with antiviral, anti-inflammatory and antibacterial properties.
